Gluten-related conditions, including celiac disease, wheat allergy, and non-celiac gluten sensitivity, may produce identical symptoms, making accurate diagnosis challenging. When medically necessary, this testing will provide clinicians useful diagnostics to determine the specific cause of symptoms reported as a gluten sensitivity.
The True Health Celiac Disease and Gluten Sensitivity Profile incorporates seven FDA-approved specific wheat-based serologic markers that can differentiate wheat allergy, celiac disease, and non-celiac gluten sensitivity.
Biomarkers included are available to order as individual tests, or as a comprehensive profile to help provide simultaneous diagnostic information about multiple conditions in a single blood draw.
Results from True Health's comprehensive testing offer a gateway to additional clinical assessment and effective patient management.
True Health Group is focused on transforming patient care through integrated diagnostics and healthcare services. True Health Diagnostics, a subsidiary, specialises in earlier-stage diagnosis and prevention of chronic disease, including cardiovascular, diabetes, cancer, genetic disorders, autoimmune disease, and more.
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
GSK wins European Commission approval for Shingrix prefilled syringe
Abbott launches Libre Assist for in-the-moment food decisions
RedHill advances RHB-102 across GI indications
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
Samsung Bioepis begins direct commercialisation of BYOOVIZ in Europe
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
Qlife's Egoo Health platform selected for major AI-driven diabetes and MASLD project in China
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes
Innovent Biologics reports primary and all key secondary endpoints met in mazdutide Phase 3 trial
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Adocia files patent for long-acting peptide platform AdoXLong and updates on BioChaperone studies